Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and ...

GeoVax Labs (GOVX) announced its endorsement of President Donald J. Trump’s Stargate Initiative, “which aims to harness advanced technologies ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been given an average rating of “Buy” by the seven analysts ...

This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine ...

ATLANTA, GA - January 29, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted that it is ...

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market capitalization of $19.78 million, announced today that its shareholders have approved ...

The upcoming Phase 2 trial will evaluate the efficacy of Gedeptin in combination with ICIs in patients with first-recurrence head and neck cancer. Key endpoints will include pathologic response rates ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well-being of all.